Items where authors include "Ralph, C."

Article

Collinson, F. orcid.org/0000-0001-6964-6406, Royle, K.-L. orcid.org/0000-0003-0225-1199, Swain, J. orcid.org/0000-0003-2729-3029 et al. (28 more authors) (2024) Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment, 28 (45). ISSN 1366-5278

Rescigno, P., Porta, N., Finneran, L. et al. (26 more authors) (2024) Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial. European Journal of Cancer, 205. 114103. ISSN 0959-8049

Motzer, R.J., Porta, C., Eto, M. et al. (238 more authors) (2024) Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology, 42 (11). pp. 1222-1228. ISSN 0732-183X

Asif, A., Chan, V.W.-S. orcid.org/0000-0002-6108-9315, Osman, F.H. et al. (12 more authors) (2023) The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Small Renal Cell Carcinomas after Image-Guided Cryoablation or Radio-Frequency Ablation. Cancers, 15 (7). 2187. ISSN 2072-6694

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Chan, V.W.-S. orcid.org/0000-0002-6108-9315, Osman, F.H., Cartledge, J. et al. (9 more authors) (2022) Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma. European Radiology, 32 (9). pp. 5811-5820. ISSN 0938-7994

Wah, T.M., Lenton, J., Smith, J. et al. (7 more authors) (2021) Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience. European Radiology, 31 (10). pp. 7491-7499. ISSN 0938-7994

Ng, H., Chan, V.W.-S. orcid.org/0000-0002-6108-9315, Cartledge, J. et al. (8 more authors) (2021) Iatrogenic ureteric stricture post image guided renal cryoablation in a patient with von hippel-lindau syndrome. Radiology Case Reports, 16 (8). pp. 1980-1984. ISSN 1930-0433

Zhong, J., Palkhi, E., Buckley, D.L. et al. (7 more authors) (2021) Feasibility study on using dynamic contrast enhanced MRI to assess the effect of tyrosine kinase inhibitor therapy within the STAR trial of metastatic renal cell cancer. Diagnostics, 11 (7). 1302. ISSN 2075-4418

Müller, L.M.E., Migneco, G., Scott, G.B. et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426

Ng, H., Wang, K., Cartledge, J. et al. (11 more authors) (2020) Urinothorax following percutaneous image-guided renal cryoablation. Radiology Case Reports, 15 (11). pp. 2348-2352. ISSN 1930-0433

Powles, T., Lackner, M.R., Oudard, S. et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 34 (14). 1660-U204. ISSN 0732-183X

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534